Eli Lilly ( LLY 1.07%) and Novo Nordisk ( NVO -1.99%) are two of the most valuable healthcare stocks in the world, largely ...

New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

Novo Nordisk said an agreement reached last year with privately held Lexington, Mass. company Valo Health that initially was valued at up to $2.7 billion is now been expanded to a $4.6 billion deal.

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

Holiday whiplash over CTA enforcement, Nvidia stock pops on CES keynote, weight loss drugs drive healthcare costs up.

The epicentre was around 80 km north of Mount Everest, the world's highest mountain and a popular destination for climbers and trekkers. Asia Pacificcategory Tremors in earthquake-prone Tibet 12: ...